Radiopharm Theranostics

[Not Yet Scheduled]
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (ticker: RAD) since November 2021. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be First to Market or Best in Class.
Ticker:
RAD
Exchange:
ASX
Company Type:
Publicly Traded Company
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2021
Main Therapeutic Focus:
Lead Product in Development:
Nanomabs, IntegrinAvB6, Pivalate, PSAmAb
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Radiopharm Theranostics